Brief: Biomx Announces Preclinical Results Of Analysis Of Patient Samples And Engineering Of Phage For Therapeutic Applications In Colorectal Cancer
09/12/2020 21:30
Biomx Inc PHGE.A :
* BIOMX ANNOUNCES PRECLINICAL RESULTS OF ANALYSIS OF PATIENT
SAMPLES AND ENGINEERING OF PHAGE FOR THERAPEUTIC APPLICATIONS IN
COLORECTAL CANCER
* BIOMX INC - SPECIFIC TARGETABLE BACTERIA OBSERVED IN OVER
80
PERCENT OF PATIENT COLORECTAL TUMOR SAMPLES
Source text for Eikon: ID:nBw4hpk8ca
Further company coverage: PHGE.A
Recent news on Biomx
See all newsBrief: Biomx Inc - Buys 100% Of Zorronet From Water Io - SEC Filing
Brief: BiomX Obtains Option To Acquire Control Of Israeli Laser-Radar Counter-Drone System
Brief: Biomx Adds Former Mossad Deputy To Advisory Board
Brief: Biomx Inc - Jonathan Solomon Resigns As CEO And Board Member Effective March 4, 2026 - SEC Filing
Brief: BiomX Says Unaware of Any Undisclosed Developments Amid Unusual Stock Trading